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expressed in E. coli and tested for binding to TIMP-3 by both plate-
and bead-based binding assays. Sequences that bound TIMP-3
were tested for interference with TIMP-3’s inhibition of MMP-13,
using a ﬂuorescence-quench substrate, and for promotion of TIMP-
3 accumulation in HTB-94 cell cultures. TIMP-3 in the media was
assayed by western blot and ELISA. Internalization of exogenous
TIMP-3 was examined by confocal microscopy with A549 cells:
cells were incubated typically with 1 ug/ml TIMP-3 for 30 minutes
at 4 degrees, with or without various pre-treatments, then washed,
ﬁxed and stained with a ﬂuorescently labeled anti-TIMP-3 antibody,
or washed and then incubated further at 4 or 37 degrees before
ﬁxation and staining.
Results: Multiple ecto-domain LRP-1 sequences bound TIMP-3
with submicromolar afﬁnity, including Cluster II (which contains
8 ligand binding domains) and parts of Cluster IV. The Cluster
IV sequences substantially impaired TIMP-3’s inhibition of MMP-
13, but Cluster II had a minimal effect on this inhibitory activity.
Moreover, Cluster II caused an accumulation of TIMP-3 in HTB-
94 cell cultures comparable to that seen in the presence of
heparin, which is believed to prevent TIMP-3 from binding to the
cell surface. Cells that lack LRP-1 were found to accumulate
TIMP-3 in the medium to a greater extent than wild-type cells.
The confocal microscopic analysis showed that TIMP-3 binds
to the cell surface by a heparin-competible mechanism, rapidly
disappears when the cells are incubated at 37 degrees but not at
4 degrees, and accumulates inside the cells if they are pre-treated
with chloroquine to prevent lysosomal degradation.
Conclusions: TIMP-3 can bind directly to the LRP-1 scavenger
receptor. Some TIMP-3-binding fragments of the receptor reduce
the inhibitor’s activity against metalloproteases, but others do not,
and one of these causes an accumulation of TIMP-3 in tissue
culture medium. LRP-1 is required for normal clearance of TIMP-
3, which entails binding to the cell surface, internalization, and
degradation by lysosomes.
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Purpose: Background: Several Hyaluronic acids (HA) are cur-
rently available for the management of KOA. Some assertions
have been made regarding a potential better efﬁcacy of the high-
est MW products. However, results of existing published trials are
controversial.
Objectives: To compare the efﬁcacy and safety of a "medium" MW
(F60027, Structovial) and a "high" MW (Hylan G-F 20, Synvisc)
HA on function and pain in KOA.
Methods: We conducted a multicentre, double-blind (injector and
clinical assessor blinded to each other), active controlled, parallel-
group study, according to a non-inferiority design. Patients aged 50
- 75 years with symptomatic KOA (ACR criteria) were randomized
to receive 3 intra-articular injections at weekly intervals of either
F60027 or Hylan G-F20. Inclusion criteria were: global pain in
the target knee > or = 40 mm on a 100-mm visual analog scale
(VAS), Lequesne’s Algofunctional Index (LFI) score > 7 (range: 0-
24) and radiological Kellgren-Lawrence grade 2 or 3. The primary
outcome was the LFI score change between baseline and week
24. Secondary assessments were pain VAS, quality of life (SF-12),
patient’s and physician’s global assessments on VAS at baseline,
weeks 1, 2, 6, 12, 18 and 24. Safety was assessed by recording
any adverse events. A non-inferiority test was assessed: 95%
conﬁdence interval (CI) of the difference F60027 - Hylan G-F20
on change of LFI score. Pre-determined non inferiority limit was
settled as the lower limit of the 95% CI above -1.25.
Results: 279 patients were randomized: 276 analyzed in the full
analysis dataset (FAS), 236 in the per protocol (PP) analysis. No
difference between groups at entry regarding demographics and
disease characteristics. The main efﬁcacy analysis (PP) showed
no difference between F60027 and Hylan G-F20 on mean vari-
ations of the LFI score over 24 weeks which varied by -4.67
(0.27) in F60027 group and -4.54 (0.28) in Hylan G-F20 group ;
difference = 0.132 [95%CI: -0.598, 0.861]. The -0.598 lower limit
of the CI was above the pre-trial selected non inferiority margin
of -1.25, which clearly demonstrated the non inferiority of F60027
compared to Hylan G-F20. The analysis on the FAS gave similar
results. Analyses of the secondary efﬁcacy endpoints on both
PP/FAS populations showed the same trends for each treatment
with improvements of clinical relevance of all outcomes at week
24. Improvement on function and pain translated into an improve-
ment on the physical component of SF12. Maximum improvement
was achieved at week 6 and maintained up to week 24. Changes
of the LFI score between baseline and week 24 were -5.73 in
the F60027 group and -5.57 in the Hylan G-F20 group giving an
intra-group effect size of 1.48 and 1.44 respectively.
Both treatments were well tolerated. Local reactions such as pain
at injection site were reported in 3.6% of patients in each group.
Conclusions: F60027 and Hylan G-F20 were equally effective in
reducing functional impairment and pain over a 6 month period of
time in KOA patients, without any safety concerns.
507
CONCOMITANT COMBINATION INTRA-ARTICULAR
HYALURONIC ACID AND CATIONIC ARTICULAR BRACE
THERAPY FOR ADVANCED OSTEOARTHRITIS OF THE
KNEE: A CASE REPORT
J.P. Figueroa
Harrington Mem. Hosp., Southbridge, MA
Purpose: Intra-articular hyaluronic acid (HA) injections of the knee
have been established to both lubricate and replenish the surface
cartilage of the knee joint. This is accomplished when HA stim-
ulates chondrocytes to produce a substance that is similar to
cartilage. The cationic articular brace (CAB) functions by stimulat-
ing chondrocytes at a particular electromagnetic frequency which
can lead to the production of more cartilage. Over the course of
two years approximately 30% of patients treated with this brace
can demonstrate an increase in joint space by MRI associated
with functional and symptomatic improvement.
In this case presentation of advanced osteoarthritis of the knee,
serial intra-articular HA injections when tried singularly provided
only minimal pain relief. The patient’s cardiac status eliminated
surgery as a therapeutic option. Symptomatically the patient’s
pain severely impaired his ability to ambulate. It was only when
the concomitant combination of intra-articular HA injections and
CAB therapy was used for his knee that the patient’s pain was
sufﬁciently relieved such that he was able to increase his ability to
ambulate.
Methods: For approximately a 1 year period the patient recieved
2 cycles of intra-articular HA injections to both knees. The symp-
tomatic and functional beneﬁt was noted. Then over a 2 year
